بررسی اثربخشی قرص کورکومین در درمان بیماری کبد ‌چرب غیر ‌الکلی: یک مطالعه‌ی کارآزمایی بالینی

نوع مقاله : مقاله های پژوهشی

نویسندگان

1 استادیار، گروه داخلی، دانشکده‌ی پزشکی و مرکز تحقیقات اختلالات متابولیک استخوانی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

2 دستیار، گروه داخلی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

3 فوق تخصص بیماری‌های گوارش و کبد، گروه داخلی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

4 گروه اپیدمیولوژی و آمار زیستی، دانشکده‌ی بهداشت، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

چکیده

مقدمه: بیماری کبد‌ چرب غیر‌ الکلی (Non-alcoholic fatty liver disease یا NAFLD) شایع‌ترین نوع بیماری کبد‌ در سراسر جهان است. با توجه به شیوع بالای NAFLD، برخی بیماران تمایل به مصرف داروهای گیاهی برای درمان دارند. هدف از انجام مطالعه‌ی حاضر، بررسی تأثیر قرص کورکومین بر NAFLD بود.روش‌ها: در این مطالعه‌ی کارآزمایی بالینی، 100 بیمار با NAFLD وارد مطالعه شدند. در بدو ورود به مطالعه، قد، وزن و شاخص توده‌ی بدنی بیماران اندازه‌گیری شد. همچنین، آزمایش‌های عملکرد کبد ‌و سونوگرافی کبد ‌برای آنان صورت گرفت. سپس، بیماران به دو گروه مورد و شاهد تقسیم شدند و به ترتیب، به مدت هشت هفته از کورکومین و دارونما استفاده کردند. همچنین، در قبل و بعد‌ از ‌مداخله، سطح قند خون ناشتا (Fasting blood sugar یا FBS) و پروفایل لیپیدی (شامل کلسترول تام، تری‌گلیسیرید، Low-density lipoprotein (LDL) و High-density lipoprotein (HDL)، Human C-reactive protein (h-CRP) و نشانگرهای عملکرد کبدی مانند Alanine transaminase (ALT)، Alkaline phosphatase (ALP)، Aspartate aminotransferase (AST) بیماران اندازه‌گیری و ثبت شد. اطلاعات جمع‌آوری شده در نرم‌افزار SPSS وارد و در بین دو گروه ‌مورد مقایسه قرار گرفت.یافته‌ها: جنسیت، سن، کلسترول تام، تری‌گلیسیرید، LDL و HDL، FBS، نشانگرهای عملکرد کبدی AST، ALT، ALP، hCRP و درجه‌ی کبد ‌چرب بیماران در قبل‌ از‌ مداخله بین دو‌ گروه‌ مورد ‌مطالعه اختلاف نداشت (050/0 > P)، اما سطوح ALT، AST و hCRP پس از مداخله در گروه ‌مورد به طور معنی‌داری کاهش یافت (001/0 > P).نتیجه‌گیری: بر طبق نتایج مطالعه‌ی حاضر، به نظر می‌رسد که مصرف کورکومین می‌تواند پیشنهاد مناسبی برای درمان NAFLD باشد.

کلیدواژه‌ها


عنوان مقاله [English]

The Effect of Curcumin Pill in Treatment of Non-alcoholic Fatty Liver Disease: A Clinical Trial Study

نویسندگان [English]

  • Bahram Pakzad 1
  • Arash Hedayat 2
  • Mehdi Ahmadian 3
  • Amin Bagheri-Ghalehsalimi 2
  • Mojtaba Akbari 4
1 Assistant Professor, Department of Internal Medicine, School of Medicine AND Isfahan Bone Metabolic Disorders Research Center, Isfahan University of Medical Sciences, Isfahan Iran
2 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Gastroenterologist, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Science, Isfahan, Iran
چکیده [English]

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common type of liver disease across the world. Due to the high prevalence of NAFLD, some patients tend to use herbal medicines for its treatment. The aim of the present study was to evaluate the effects of curcumin pill on NAFLD.Methods: In this clinical trial study, 100 patients with NAFLD were enrolled. Then, their height, weight, and body mass index were measured, and liver function tests and liver ultrasound were performed, too. The patients were then divided into two groups of case and control, and received curcumin and placebo for eight weeks, respectively. Before and after intervention, fasting blood sugar (FBS), lipid profile levels [including total cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein (HDL)], human C-reactive protein (hCRP) level, and liver markers such as aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine transaminase (ALT) were measured and recorded again. Data were analyzed and compared between two groups using SPSS software.Findings: There was no significant difference between the two groups in terms of gender, age, clinical features, total cholesterol, triglyceride, LDL, HDL, FBS, liver function markers such as ALP, ALT, and AST, and hCRP, and fatty liver grade at the onset of the study (P > 0.050). However, the level of ALT, AST, and hCRP significantly reduced in the case group after the intervention (P < 0.001).Conclusion: According to the results of the present study, it seems that curcumin can be recommended for appropriate treatment of NAFLD.

کلیدواژه‌ها [English]

  • Curcumin
  • Non-Alcoholic Fatty Liver Disease
  • Treatment
  1. Namakin K, Hosseini M, Zardast M, Mohammadifard M. Prevalence of non-alcoholic fatty liver disease (NAFLD) and its clinical characteristics in overweight and obese children in the south east of Iran, 2017. Hepat Mon 2018; 18(12): e83525.
  2. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52(1): 79-104.
  3. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 2013; 39(1): 2-13.
  4. Zabihi NA, Pirro M, Johnston TP, Sahebkar A. Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des 2017; 23(7): 969-82.
  5. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 1999; 39(1): 41-7.
  6. Um MY, Hwang KH, Ahn J, Ha TY. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 2013; 113(3): 152-7.
  7. Vizzutti F, Provenzano A, Galastri S, Milani S, Delogu W, Novo E, et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest 2010; 90(1): 104-15.
  8. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 1992; 36(4): 273-5.
  9. Xie YL, Chu JG, Jian XM, Dong JZ, Wang LP, Li GX, et al. Curcumin attenuates lipopolysaccharide/d-galactosamine-induced acute liver injury by activating Nrf2 nuclear translocation and inhibiting NF-kB activation. Biomed Pharmacother 2017; 91: 70-7.
  10. Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr 2019; 73(3): 441-9.
  11. Wei Z, Liu N, Tantai X, Xing X, Xiao C, Chen L, et al. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Hepatol Int 2019; 13(3): 302-13.
  12. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 2001; 131(11): 2932-5.
  13. Ayoubi A, Valizadeh R, Omidi A, Abolfazli M. Evaluation of turmeric (Curcuma longa) effects in preventing consequences of lead acetate in male rats. J Birjand Univ Med Sci 2014; 21(1): 68-76. [In Persian].
  14. Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008; 52(9): 995-1004.
  15. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int 2009; 29(10): 1457-66.
  16. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial. J Cardiovasc Pharmacol 2016; 68(3): 223-9.
  17. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial. Phytother Res 2016; 30(9): 1540-8.
  18. Naik SR, Thakare VN, Patil SR. Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: Evidence of its antioxidant property. Exp Toxicol Pathol 2011; 63(5): 419-31.
  19. Li B, Wang L, Lu Q, Da W. Liver injury attenuation by curcumin in a rat NASH model: An Nrf2 activation-mediated effect? Ir J Med Sci 2016; 185(1): 93-100.
  20. Zhao NJ, Liao MJ, Wu JJ, Chu KX. Curcumin suppresses Notch1 signaling: Improvements in fatty liver and insulin resistance in rats. Mol Med Rep 2018; 17(1): 819-26.